Intrexon | XON - Ebitda


Intrexon reported $-24.7M in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 367.97M 46.53M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD 17.92M 8.17M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Roche Holding CHF 12.68B 2.36B Jun/2024
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
Veracyte USD 42.31M 2.58M Dec/2025
Xencor USD -51.05M 55.28M Dec/2025